Department of Nuclear Medicine, Sant' Orsola-Malpighi Hospital, Bologna, Italy.
Eur J Radiol. 2012 May;81(5):988-1001. doi: 10.1016/j.ejrad.2011.03.020. Epub 2011 Mar 31.
Lung cancer (LC) still represents one of the most common tumours in both women and men. PET/CT is a whole-body non-invasive imaging procedure that has been increasingly used for the assessment of LC patients. In particular, PET/CT added value to CT is mainly related to a more accurate staging of nodal and metastatic sites and to the evaluation of the response to therapy. Although the most common PET tracer for LC evaluation is 18F-FDG, new tracers have been proposed for the evaluation of lung neuroendocrine tumours (68Ga-DOTA-peptides, 18F-DOPA) and for the assessment of central nervous system metastasis (11C-methionine). This review focuses on the main clinical applications and accuracy of PET/CT for the detection of non-small cells lung cancer (NSCLC), broncho-alveolar carcinoma (BAC), small cells lung cancer (SCLC), lung neuroendocrine tumours (NET) and solitary pulmonary nodules (SPN).
肺癌（LC）仍然是男女中最常见的肿瘤之一。PET/CT 是一种全身无创成像程序，已越来越多地用于 LC 患者的评估。特别是，PET/CT 相对于 CT 的附加价值主要与更准确地分期淋巴结和转移部位以及评估治疗反应有关。尽管用于评估 LC 的最常见的 PET 示踪剂是 18F-FDG，但已经提出了新的示踪剂用于评估肺神经内分泌肿瘤（68Ga-DOTA-肽，18F-DOPA）和评估中枢神经系统转移（11C-蛋氨酸）。这篇综述重点介绍了 PET/CT 在检测非小细胞肺癌（NSCLC）、细支气管肺泡癌（BAC）、小细胞肺癌（SCLC）、肺神经内分泌肿瘤（NET）和孤立性肺结节（SPN）方面的主要临床应用和准确性。
